Skip to main content
SpringerLink
Log in

5-Hydroxytryptamine receptor antagonists as antihypertensive drugs

  • Chapter
Cardiovascular Pharmacology of 5-Hydroxytryptamine

Abstract

Though 5-hydroxytryptamine (5-HT) exerts powerful pharmacological effects on the heart and blood vessels [1, 2], the physiological role of 5-HT in cardiovascular regulation is not clear. The effect of 5-HT on arterial blood pressure is triphasic [3] and consists mainly of an initial short-lasting depressor phase due to the Von Bezold-Jarisch reflex mediated by 5-HT3 receptors [4–7], followed by a 5-HT2 receptor-mediated hypertensive phase [5, 6, 8], and a late, long-lasting, hypotensive phase mediated by 5-HT1like receptor stimulation [see 9]. It is, therefore, obvious that only antagonists at 5-HT2 receptors may be expected to have an antihypertensive effect in the event that these receptors are involved in the pathophysiology of hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Saxena PR (1986): Nature of the 5-hydroxytryptamine receptors in mammalian heart. Prog Pharmacol 6: 173–185.

    CAS  Google Scholar 

  2. Cohen ML (1989): Receptors for 5-hydroxytryptamine in the cardiovascular system. Ch. XXII, This book.

    Google Scholar 

  3. Page IH (1957): Cardiovascular actions of serotonin (5-hydroxytryptamine), pp. 93–108 in: Lewis GP (ed), 5-Hydroxytryptamine. London: Pergamon Press.

    Google Scholar 

  4. Fozard JR (1984): MDL 72222: a potent and highly selective antagonist at neuronal 5-HT receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36–44.

    Article  CAS  PubMed  Google Scholar 

  5. Kalkman HO, Engel G, Hoyer D (1984): Three distinct types of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats. J Hypertens 6 (suppl. 2): S421–S428.

    Google Scholar 

  6. Saxena PR, Lawang A (1985): A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1-like receptors. Arc Int Pharmacodyn Ther 227: 235–252.

    Google Scholar 

  7. Saxena PR, Mylecharane EJ, Heiligers J (1985): Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation by 5-HT1-like receptors. Naunyn Schmiedebergs Arch Pharmacol 330: 121–129.

    Article  CAS  PubMed  Google Scholar 

  8. Leysen JE, De Chaffoy De Courcelles D, De Clerck F, Niemegeers CJE, Van Nueten JM (1984): Serotonin-S2 receptor binding sites and functional correlates. Neuropharmacology 23: 1493–1501.

    CAS  Google Scholar 

  9. Saxena PR, Bolt GR, Dhasmana KM (1987): Serotonin agonists and antagonists in experimental hypertension. J Cardiovasc Pharmacol 10 (suppl. 3): S12–S18.

    Article  Google Scholar 

  10. Bolt GR, Saxena PR (1985): Cardiovascular profile and hypotensive mechanism of ketanserin in the rabbit. Hypertension 7: 499–506.

    Article  CAS  PubMed  Google Scholar 

  11. Vanhoutte PM, Ball SG, Berdeaux A, Cohen ML, Hedner T, McCall R, Ramage AG, Reimann IH, Richer C, Saxena PR, Schalekamp MADH, Struyker-Boudier HAJ, Symoens J, Van Nueten JM, Van Zwieten PA (1986): Mechanism of action of ketanserin in hypertension. Trends Pharmacol Sci 7: 58–59.

    Article  CAS  Google Scholar 

  12. Vanhoutte PM, Amery A, Birkenhäger W, Breckenridge A, Bühler F, Distler A, Dormandy J, Doyle A, Frohlich E, Hansson L, Hedner T, Hollenberg N, Jensen H-E, Lund-Johansen P, Meyer P, Opie L, Robertson I, Safar M, Schalekamp M, Symoens J, Trap-Jensen J, Zanchetti A (1988): Serotonergic mechanisms in hypertension: Focus on the effects of ketanserin. Hypertension 11: 111–133.

    Article  CAS  PubMed  Google Scholar 

  13. Van Nueten JM, Schuurkes JAJ, De Ridder WJE, Kuyps JJMD, Janssens WJ (1986): Comparative pharmacological profile of ritanserin and ketanserin. Drug Dev Res 8: 187–195.

    Article  Google Scholar 

  14. Van Nueten JM, Xhonneux R, Janssens WJ, Schuurkes JAJ, Janssen PAJ (1988): Interaction between S2-serotonergic and alpha1-adrenergic receptors and control of blood pressure, (in press) in: Vanhoutte PM (ed), Mechanism of Vasodilatation. New York: Raven Press.

    Google Scholar 

  15. Blauw GJ, van Brummelen P, Chang PC, Van Zwieten PA (1988): Regional vascular effects of serotonin and ketanserin in young, healthy subjects. Hypertension 11: 256–263.

    Article  CAS  PubMed  Google Scholar 

  16. Wenting GJ, Manin’t Veld AJ, Woittiez AJJ, Boomsma F, Schalekamp MADH (1982): Haemodynamic effects of ketanserin, a selective 5-hydroxytryptamine (serotonin) receptor antagonist, in essential hypertension. Clin Sci 63:435S–438S.

    Google Scholar 

  17. Janssen PAJ (1985): Pharmacology of potent and selective S2-serotonergic antagonists. J Cardiovasc Pharmacol 1 (suppl. 7): S2–S11.

    Article  Google Scholar 

  18. Symoens J, Vanhoutte PM (1985): The role of serotonin in blood pressure regulation, pp. 141–164 in: Smith JAR, Watkins J (eds), Care of the postoperative patient. London: Butterworth.

    Google Scholar 

  19. Cohen ML, Fuller RW, Kurz KD (1983): LY 53857, a selective new potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat. J Pharmacol Exp Ther 221 : 327–332.

    Google Scholar 

  20. Kalkman HO, Harms YM, Van Gelderen EM, Batink HD, Timmermans PBMWM, Van Zwieten PA (1983) Hypotensive activity of serotonin antagonists; correlation with α1-adrenoceptor and serotonin receptor blockade. Life Sci 32: 1499–1505.

    Article  CAS  PubMed  Google Scholar 

  21. Hosie J, Stott DJ, Robertson JIS, Ball SG (1987): Does acute serotenergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension. J Cardiovasc Pharmacol 10 (suppl. 3): S86–S88.

    Article  Google Scholar 

  22. Van Zwieten PA, Mathy MJ, Boddeke HWGM, Doods HN (1987): Central hypotensive activity of ketanserin in cats. J Cardiovasc Pharmacol 10 (suppl 3): S54–S58.

    Article  Google Scholar 

  23. Blackburn TP, Haworth SJ, Jessup CL, Morton PB, Williams C (1989): ICI 170809, A selective 5-hydroxytryptamine antagonist, inhibits human platelet aggregation in vitro and exvivo. Ch. XXXX, This book.

    Google Scholar 

  24. Fozard JR (1982): Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4: 829–838.

    Article  CAS  PubMed  Google Scholar 

  25. Kalkman HO, Timmermans PBMWM, Van Zwieten PA (1982): Characterization of the antihypertensive properties of ketanserin (R41468) in rats. J Pharmacol Exp Ther 222: 227–231.

    CAS  PubMed  Google Scholar 

  26. Wright CE, Angus JA (1983): Haemodynamic response to ketanserin in rabbits with page hypertension: Comparison with prazosin J Hypertension 1: 183–190.

    Article  CAS  Google Scholar 

  27. Reimann IW, Frohlich JC (1983): Mechanism of antihypertensive action of ketanserin in man. Br Med J 287: 381–383.

    Article  CAS  Google Scholar 

  28. Fagard R, Fioli R, Lijnen P, Staessen J, Moeman E, De Schaepdryver A, Amery A (1984): Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J 51: 149–156.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Casiglia E, Gava R, Semplicini A, Nicolin P, Pessina AC (1986): The mechanism of the antihypertensive effects of ketanserin: a comparison with metoprolol. Br J Clin Pharmacol 22: 751–752.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Berdeaux A, Edouard A, Samii K, Giudicelli JF (1987): Ketanserin and the arterial baroreceptor reflex in normotensive subjects. Eur J Clin Pharmacol 32: 27–33.

    Article  CAS  PubMed  Google Scholar 

  31. Wenting GJ, Woittiez AJJ, Manin’t Veld AJ, Schalekamp MADH (1984): 5-HT, alpha- adrenoceptors, and blood pressure; effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6:100–109.

    Article  CAS  PubMed  Google Scholar 

  32. Dragsted N, Boeck V (1988): Cardiovascular effects of irindalone, a novel 5-HT2 antagonist with antihypertensive activity (Abstr P43). International Congress on Cardiovascular Pharmacology of 5-HT, Oct 4–7, Amsterdam.

    Google Scholar 

  33. Schröder G, Beckmann R, Müller B, Schulz BG, Stock G (1988): Pharmacological profile of ZK 33.839, a new 5-HT2/a1 -antagonist (Abstr P38). International Congress on Cardiovascular Pharmacology of 5-HT, Oct 4–7, Amsterdam.

    Google Scholar 

  34. Van der Starre PJA (1988): Ketanserin and hypertension in cardiac surgery. Thesis, State University of Limburg, Maastricht, The Netherlands.

    Google Scholar 

  35. Herrmann WM, Baumgartner P (1986): Combined pharmaco-EEG and pharmacopsy- chological study to estimate CNS effects of ketanserin in hypertensive patients. Neuropsychobiology 16: 47–56.

    Article  CAS  PubMed  Google Scholar 

  36. McCall RB, Schuette MR (1984): Evidence for an alpha-1 receptor-mediated central sympathoinhibitory action of ketanserin. J Pharmacol Exp Ther 228: 704–710.

    CAS  PubMed  Google Scholar 

  37. Ramage AG (1985): The effects of ketanserin, methysergide and LY 53857 on sympathetic nerve activity. Eur J Pharmacol 113: 295–303.

    Article  CAS  PubMed  Google Scholar 

  38. Hedner T, Pettersson A, Gradin K, Persson B (1986): Peripheral serotonergic mecha- nsims in cardiovascular regulation in the spontaneously hypertensive rat. J Hypertension 4 (suppl. 3): S223–S225.

    Google Scholar 

  39. Copeland IW, Bentley GA (1985): A possible central action of prazosin and ketanserin to cause hypotension. J Cardiovasc Pharmacol 7: 822–825.

    Article  CAS  PubMed  Google Scholar 

  40. Dhasmana KM, Banerjee AK, Saxena PR (1989): The effects of intrathecal ketanserin and phentolamine on heart rate and arterial blood pressure in the rat. Ch. XXX, This book.

    Google Scholar 

  41. Phillips CA, Mylecharane EJ, Markus JK, Shaw J (1985): Hypotensive actions of ketanserin in dogs: involvement of a centrally mediated inhibition of sympathetic vascular tone. Eur J Pharmacol 111: 319–327.

    Article  CAS  PubMed  Google Scholar 

  42. Woittiez AJJ, Wenting GJ, Van der Meiracker AH, Ritsma Van Eck HJ, Manin’t Veld AJ, Zantvoort FA, Schalekamp MADH (1986): Chronic effect of ketanserin in mild to moderate essential hypertension. Hypertension 8: 167–173.

    CAS  Google Scholar 

  43. Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson B, Saxena PR (1986): Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–575.

    Article  CAS  PubMed  Google Scholar 

  44. Antonaccio MJ, Taylor DJ (1977): Reduction in blood pressure, sympathetic nerve discharge and centrally evoked pressor responses by methysergide in anaesthetized cats. Eur J Pharmacol 42: 331–338.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. Pramod R. Saxena
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacology, Erasmus University, Rotterdam, The Netherlands

    P. R. Saxena

  2. Department of Physiology, University of Wales, College of Cardiff, Cardiff, UK

    D. I. Wallis

  3. Department of Pharmacology, Duphar B.V, Weesp, The Netherlands

    W. Wouters  & P. Bevan  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Saxena, P.R. (1990). 5-Hydroxytryptamine receptor antagonists as antihypertensive drugs. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (eds) Cardiovascular Pharmacology of 5-Hydroxytryptamine. Developments in CardioCardiovascular Pharmacology of 5-Hydroxytryptamine, vol 106. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0479-8_24

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-0479-8_24

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6701-0

  • Online ISBN: 978-94-009-0479-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation